文献速递脊柱关节炎

非甾体抗炎药对强直性脊柱炎患者8年主要心血管事件累积发病率的影响:一项全国性研究

Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该法国全国队列研究纳入2010至2013年新获强直性脊柱炎长期疾病计划资格的22929例患者,随访至2018年12月31日。8年主要不良心血管事件、卒中和心肌梗死的累积发病率分别为1.81%、0.97%和0.85%。非甾体抗炎药(SHR 0.39)和抗肿瘤坏死因子(SHR 0.61)与主要不良心血管事件风险降低相关,抗白介素17未显示关联。

要点

  • 强直性脊柱炎患者8年主要不良心血管事件累积发病率为1.81%。
  • 非甾体抗炎药与主要不良心血管事件风险降低相关(SHR 0.39)。
  • 抗肿瘤坏死因子与主要不良心血管事件风险降低相关(SHR 0.61)。

核心结论

  • 强直性脊柱炎患者新获长期疾病计划资格后8年主要不良心血管事件发病率较低。
  • 结果支持非甾体抗炎药和抗肿瘤坏死因子在心血管风险中具有保护作用的假说。

研究设计与样本

  • 基于法国国家医疗行政数据库SNDS的全国队列研究。
  • 纳入2010至2013年新获长期疾病计划资格的强直性脊柱炎患者共22929例,平均年龄43.0岁(标准差13.9),男性44.9%。
  • 最终随访日期为2018年12月31日。
  • 采用倾向性评分和逆概率加权的竞争风险分析计算累积发病率函数和亚风险比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to describe the incidence of major adverse cardiovascular events (MACEs) in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. METHODS: This national cohort study was based on the French national medico-administrative database SNDS containing data on hospitalization, the LTI, and outpatient care consumption. All French patients newly receiving LTI benefits for AS from 2010 to 2013 were included. The final follow-up date was 31 December 2018. The occurrences of MACEs [stroke and myocardial infarction (MI)] and comorbidities were identified from algorithms previously described in the literature. Competitive risk analysis using propensity score and inverse weighting was performed to calculate cumulative incidence functions and to determine subhazard ratios (SHRs) for the various treatments of interest. RESULTS: Between 2010 and 2013, 22 929 patients were included [mean age 43.0 (s.d. 13.9) years, 44.9% mal]. The 8-year cumulative incidences of MACE, stroke, and MI were 1.81% (1.61-2.05), 0.97% (0.83-1.14), and 0.85% (0.71-1.04), respectively. NSAIDs [SHR: 0.39 (0.32-0.50), P < 0.001] and anti-TNF [SHR 0.61 (0.46-0.80), P < 0.001], but not anti-IL17 [2.10 (0.79-5.57)] were associated with a lower risk of MACE occurrence. CONCLUSION: MACE incidence rates at 8 years are low in patients newly benefiting from LTI for AS. Our results support the hypothesis of a protective role of NSAIDs and anti-TNF in cardiovascular risk in these patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fakih O, Desmarets M, Martin B, et al. Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). 2023. PMID: 36752498. doi:10.1093/rheumatology/kead072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。